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ABSTRACT
Current management of glaucoma entails the
medical, laser, or surgical reduction of
intraocular pressure (IOP) to a predetermined
level of target IOP, which is commensurate with
either stability or delayed progression of visual
loss. In the published literature, the hypothesis
is often made that IOP control implies a single
IOP measurement over time. Although the
follow-up of glaucoma patients with single
IOP measurements is quick and convenient,
such measurements often do not adequately
reflect the untreated IOP characteristics, or
indeed the quality of treated IOP control
during the 24-h cycle. Since glaucoma is a
24-h disease and the damaging effect of
elevated IOP is continuous, it is logical that we
should aim to understand the efficacy of all
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treatment options throughout the 24-h period.
This article first reviews the concept and value
of diurnal and 24-h IOP monitoring. It then
critically evaluates selected available evidence
on the 24-h efficacy of medical, laser and
surgical therapy options. During the past
decade several controlled trials have
significantly enhanced our understanding on
the 24-h efficacy of all glaucoma therapy
options. Nevertheless, more long-term
evidence is needed to better evaluate the 24-h
efficacy of glaucoma therapy and the precise
impact of IOP characteristics on glaucomatous
progression and visual prognosis.
Keywords: 24-h efficacy; 24-h intraocular
pressure control; Circadian intraocular
pressure characteristics; Diurnal intraocular




Recent randomized controlled trials show that
reduction in intraocular pressure (IOP) results in
reduction in the rate of visual loss in most
glaucoma patients [1]. In many studies the
assumption is made that IOP control implies a
single, or occasionally, a few daytime IOP
measurements over time. Although the
follow-up of glaucoma patients with single
IOP measurements is quick and convenient,
such measurements often do not reflect IOP
control during the 24-h cycle [2–4]. Since
glaucoma is a 24-h disease and the damaging
effect of elevated IOP is continuous [5], it is
logical that we should aim to control the IOP
throughout the 24-h period. This article reviews
the value and future promise of 24-h IOP
monitoring and discusses recent 24-h efficacy
evidence on available glaucoma treatment
options. The review is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by any of the authors.
A single IOP measurement gives data for only
1min of the day andmaynot reflect the dynamic
equilibrium during the other 1439 min of that
day, or the IOP level between appointments.
Even three or fourmeasurementsmay not reflect
glaucoma status. Current routine clinical
practice involves single IOP readings at each
patient visit owing to time/cost considerations.
Consequently, the quality of IOP data, which we
rely upon to diagnose and treat glaucoma and to
choose between therapeutic options (medical,
laser, surgery) is often inadequate and can be
misleading [2, 5–11]. Ideally, a 24-h time–IOP
profile, both without and following treatment,
will optimize management and help determine
the future probability and rate of deterioration in
vision. Such data will also enhance our
understanding of the role of elevated IOP in
glaucoma initiation and progression.
The concept of 24-h IOP assessment and
control has aroused interest in recent
literature [6–27] and its application may
hold future promise. Twenty-four-hour
blood pressure monitoring is widely
employed to assist patient management.
Similarly, 24-h IOP monitoring can enhance
the quality of IOP data and guide glaucoma
management. Firstly, evaluation of untreated
24-h IOP, prior to initiation of therapy,
provides the true peak IOP and the 24-h IOP
profile. Secondly, 24-h IOP monitoring elicits
the IOP level at which damage probably
occurred and allows an optimal target IOP
to be set. Finally, the relationship between
damage and IOP is elicited in the individual
patient [3–5, 8, 9].
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The key 24-h characteristics are: (a) the mean
24-h IOP, (b) the fluctuation of 24-h IOP, and
(c) the peak 24-h IOP. As yet the value of 24-h
IOP testing in the long-term prognosis of
glaucoma remains unproven. However, those
with the worst untreated 24-h characteristics
tend to show greater deterioration. This was
demonstrated in a 24-h IOP study [7], which
found a strong linear correlation between
untreated peak IOP in exfoliation glaucoma
(XFG; r = 0.71) and primary open-angle
glaucoma (POAG; r = 0.44) and perimetric
mean deviation at the time of diagnosis. A
similar strong association was detected between
mean 24-h IOP and untreated mean visual field
loss in both XFG (r = 0.77) and POAG (r = 0.28)
[7]. Hence, it is logical to assume that the worse
24-h IOP characteristics in XFG may account for
the faster deterioration and worse prognosis.
For each patient with glaucoma, diurnal or
24-h IOP data will enhance our understanding
of the role of elevated IOP in glaucoma
initiation and progression. Although in this
context it would appear ideal to obtain
information on the 24-h control of all our
glaucoma patients this is not a realistic strategy
for most patients in most health systems. In
contrast, reliable guidance on the 24-h efficacy
of all available treatment options can be
obtained by carrying out well-designed,
randomized controlled trials, which, when
published, can influence everyday practice. For
example, a complete 24-h assessment of all
monotherapy options will allow better
separation between them and guide our
day-to-day clinical management. Then,
controlled 24-h IOP studies can supply
convincing evidence for the superiority of a
specific combined therapy regimen thus
optimizing stepwise therapy. This is supported
by previously published evidence comparing
various medical therapy regimens where the
true efficacy profile would not have been
detected if it had not been for a complete 24-h
IOP study. As evidenced by such studies, 24-h
efficacy can differ meaningfully from daytime
efficacy [10, 12–14, 21]. In the future, this
research can also remove ambiguity as to the
true efficacy of laser therapy and the overall
success of a number of novel surgical options
versus the gold standard surgical selection of
trabeculectomy with mitomycin C.
Over the last decade 24-h IOP monitoring
has allowed us to investigate the 24-h efficacy of
many new antiglaucoma drugs [7, 10, 12, 13,
15, 18, 19, 21, 23] and see the benefits of so
doing. Our results have highlighted the
unpredictability of single IOP measurements.
Patients with apparent ‘‘good IOP control’’,
often have unsatisfactory diurnal pressure
control, such as large 24-h IOP fluctuation and
undetected IOP spikes outside office hours. The
practical significance is that we now routinely
assess 24-h IOP control first before considering
other factors such as inappropriate target IOP
and compliance. To date, only Riva and
coworkers [28] have investigated the long-term
24-h IOP control in travoprost-treated patients
with POAG by performing repeated 24-h IOP
measurements over a period of 5 years while on
the same therapy. This study established that
only mean untreated 24-h IOP and treated 24-h
peak IOP during the 5-year follow-up period
were risk factors for predicting treatment failure
(P\0.01). This trial [28] demonstrated a
consistent pattern of long-term 24-h IOP
lowering (27.8–28.6%) which compares well
with the previously reported short-term 24-h
efficacy of travoprost monotherapy [6].
There is some evidence to suggest that
surgery provides better 24-h characteristics and
yields a narrower 24-h fluctuation of IOP
compared with laser and medical therapy [29,
30]. On the other hand, recent 24-h studies
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have indicated that a number of new
antiglaucoma drugs (prostaglandin analogs,
fixed combinations) significantly reduce 24-h
fluctuation of IOP [6, 12, 15, 18, 23]. It is not
known how adjunctive therapy with these
drugs compares to successful laser, or surgery.
Further research is needed on the quality of
24-h IOP control obtained with the various
therapeutic options. Little is currently known
on the relationship between 24-h IOP
characteristics with available treatment choices
and the stage of glaucoma. Despite the fact that
24-h IOP characteristics probably vary in
different types of glaucoma, our knowledge
concerning how this relates to the choice of
therapy is almost non-existent.
IOP fluctuates normally throughout the day
by around 4–6 mmHg [2, 3, 5]. In ocular
hypertensives, the diurnal fluctuation averages
6–8 mmHg, with a high of 15 mmHg possible
[1, 2, 4]. In patients with glaucoma, the 24-h
variation in IOP ranges between 6 and
15 mmHg with an upper limit of about
40 mmHg in extreme cases [2–4]. Typically, in
most 24-h studies [2, 7, 10–21] on patients with
glaucoma the untreated IOP is highest in the
morning (between 6:00 am and 12:00 pm). In
most of our patients the 10:00 am IOP
measurement yields the highest mean IOP
values [7, 12–19]. This accords with the
aqueous synthesis pattern, which is
significantly reduced during sleep at night
[31]. However, there are many exceptions to
this rule and the peak pressure may occur at any
time throughout the day. The type of glaucoma
can also influence the timing of peak IOP. In
one study [3], 45% of patients with XFG and
22.5% of those with POAG exhibited the peak
level of IOP outside office hours.
The timing and number of measurements
can obviously influence the results: more
measurements lead to more accurate 24-h IOP
profile. A potential artifact with such
measurements is the effect of hospitalization,
or the impact of stay in a sleep laboratory. This
may affect to a certain extent the pressure curve
since it can disturb the activity pattern of the
patient. However, by and large this influence
cannot be avoided. Ideally, in the future
continuous monitoring (e.g., with continuous
home tonometry utilizing IOP sensors on a
contact lens, or implants transmitting IOP data
by telemetry, etc.) may become accurate,
reliable and practical enough to find a place in
day-to-day glaucoma management.
Optimal 24-h IOP control may provide the
best long-term prognosis for chronic glaucoma.
A major breakthrough in the future may be the
development of an accurate, continuous IOP
monitoring process, which will record and
transmit IOP data every few minutes. To date
there are limited data concerning long-term
24-h IOP control with currently available
medications. The significance of specific 24-h
IOP characteristics (mean 24-h IOP, range,
maximum IOP) is not entirely understood and
their impact on long-term prognosis requires
further elucidation. It is important to document
in the future the 24-h efficacy of adjunctive
medical therapy.
PATTERNS OF 24-H IOP IN HEALTH
AND DISEASE
Pattern of IOP in Healthy Eyes
Tonometry performed over a 24-h period may
be subdivided into diurnal (daytime) and
nocturnal (nighttime) pressure measurements.
In most patients the rhythmic pattern of IOP
oscillation exhibits peaks in the morning and
troughs in the evening. In healthy
normotensive eyes, the 24-h IOP fluctuation
typically lies within a 5 mmHg range [2, 32–36].
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Drance [32] measured the IOP of 404 normal
eyes 6 times between 6:00 am and 10:00 pm and
found that 16% of these cases exhibited a
fluctuation greater than 6 mmHg, while 42%
of them exhibited their peak pressure at
06:00 am. Overall, the mean IOP fluctuation
was 3.7 ± 1.8 mmHg. Katavisto [36]
documented the highest IOP values at 8.00 am
in 41% and at midnight in over 20% of 50
subjects with normal IOP. Their 24-h
fluctuation of IOP averaged 3.17 mmHg. In the
study by David et al. [33], the peak IOP of
healthy eyes was established at the earliest
morning measurement in 40.5%, at
mid-morning in 22.6%, and at mid-day in
19% of investigated subjects. In a similar
fashion, Newell and Krill [35] studied a normal
cohort and documented the greatest frequency
of peak IOP readings between 6:00 and 8:00 am.
One important parameter that can influence
IOP fluctuation is body posture; the IOP
measured in the sitting position is generally
lower than that measured in the supine position
at any given time [22, 37–40]. In a diurnal study
performed by Chiquet and coworkers [37],
supine IOP was significantly higher than
sitting IOP, with a mean pressure difference of
2.2 ± 2.9 mmHg after 1 min, 0.9 ± 3 mmHg
after 3 min, and 1.9 ± 3.8 mmHg after 10 min
(P\0.001). Nevertheless, during a seven-day
head-down tilt bed rest, eyes seemed to
compensate for the IOP elevation after
patients assumed the head-down position and
eventually exhibited a slight and progressive
decrease of IOP (1.3 mmHg) compared to the
baseline supine IOP [37]. The decrease in IOP
reached a peak value at the end of the week of
the head-down position. In a 24-h study
conducted by Liu et al. [38], 33 volunteers
were housed in a sleep laboratory for one day
under a strictly controlled 16-h light and 8-h
dark environment and their IOP was measured
every 2 h using a pneumotonometer. In the first
group of 12 volunteers, habitual measurements
were performed with subjects seated during the
light-wake period and resting in a supine
position during the dark period [38].
Nocturnal IOP was reported to be higher than
diurnal IOP in the habitual position, with the
difference between peak to trough IOP as high
as 8.2 ± 1.4 mmHg. The increase in IOP at night
was partly attributed by the authors to an
increase in episcleral venous pressure and
redistribution of body fluid in the supine
position. In the second part of the study
performed on 21 subjects, mean IOP was
significantly higher in the dark period than in
the light-wake period [38] even when all IOP
measurements were made in the supine
position, implicating factors other than
episcleral venous pressure in the observed 24-h
IOP pattern. This group of investigators had also
showed higher mean nocturnal IOP
measurements compared to diurnal IOP levels
in habitual body position both in an aging
healthy cohort and in a group of untreated
open-angle glaucoma patients [21, 39].
IOP Pattern in Primary Open-Angle
and Normal Tension Glaucoma
In diurnal IOP monitoring studies,
approximately two-thirds of the patients with
untreated normal tension glaucoma (NTG) or
untreated POAG have been reported to display
peak IOP in the morning [33, 34, 41–43]. In the
diurnal study performed by David et al. [33], the
highest IOP was found at the earliest morning
measurement in 40% of cases, while 65% of
peak IOP readings occurred before noon. The
trough IOP measurement showed no specific
predilection for any particular time of the day
[33]. The mean fluctuation of IOP was
5.0 mmHg in normal controls, 5.8 mmHg in
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patients with glaucoma and 6.8 mmHg in
patients with ocular hypertension (OHT). In
the study by Wilensky et al. [34], a group of 176
patients with POAG, 55 subjects with OHT and
18 normal controls performed home
self-tonometry 5 times daily for 4 to 8
consecutive days. All three groups had
well-defined diurnal IOP fluctuations with
predominance of curves exhibiting morning or
mid-day peaks. In the study by Sacca et al. [41],
IOP measurements were performed on 33
healthy volunteers, 95 patients with POAG
and 50 with NTG every 2 h from 8:00 am to
8:00 pm. The highest pressure readings were
seen in the morning in all three groups, while
the lowest values were recorded in the early
afternoon period. The daily IOP fluctuations
were directly proportional to IOP levels. The
fluctuations were higher in the POAG group
(-7% to ?9.6%) than the control group (-3.4%
to ?6.9%) and the NTG group (-4.7% to
?6.4%). Collaer and coworkers [44]
investigated 53 patients with NTG, 12
glaucoma suspects, and 28 patients with POAG
and were broadly in agreement with the
previous investigations. The characteristics of
their diurnal IOP curve performed between
7:00 am and 5:00 pm were similar in all 3
patient groups: higher IOP in the early
morning, lower in the early afternoon, and a
tendency for pressure to rise again at the end of
the afternoon [44]. In this study mean diurnal
IOP fluctuation was 5 ± 2 mmHg. In a
retrospective chart review study [42], diurnal
IOP measurements of 68 untreated glaucoma
suspects and 95 patients with NTG were
performed at 10:00 am, 1:00 pm, 4:00 pm,
7:00 pm, 10:00 pm, and 7:00 am. Again in the
glaucoma suspects, the peak IOP was noted in
the morning: at 7:00 am in the right eye and at
10:00 am in the left eye. The trough IOP was
observed at 10:00 pm for both eyes. For both
eyes of patients with NTG, the peak IOP
occurred at 7:00 am and the trough IOP was
measured at 10:00 pm. In another study [43],
diurnal IOP fluctuations between 7:00 am and
10:00 pm were found to be significantly higher
in primary chronic angle-closure glaucoma
(PCACG; 7.7 ± 3.0 mmHg) and POAG
(8.3 ± 2.6 mmHg) groups compared to the
normal controls (4.8 ± 2.5 mmHg). Afternoon
peaks were more common after iridotomy in
eyes with PCACG, whereas morning peaks were
more frequent in the POAG eyes. In POAG, the
IOP fluctuations between 8:00 am and 6:00 pm
on different days were found to be broadly
similar (5.0 ± 2.6 vs. 4.0 ± 1.2 mmHg;
P = 0.08).
It is well established that 24-h IOP
monitoring may reveal higher peaks and wider
fluctuations than those recorded during office
hours [9, 11, 20, 21, 45]. Nevertheless,
conflicting results have been published as to
the time of peak pressure, the pattern of the
curve, and the extent IOP fluctuation. In some
studies, the timing of peak IOP during pressure
monitoring exhibited no apparent pattern [9,
20]. In a retrospective chart review of 18
patients with NTG and 11 with POAG using
their prescribed topical antiglaucoma
treatment, Hughes et al. [9] reported that the
mean peak IOP during 24-h monitoring was
4.9 mmHg higher than the mean peak office
IOP determined in the clinic during previous
visits, despite the fact that the mean office IOP
was similar to the mean 24-h value. The mean
24-h IOP fluctuation documented was
9.4 ± 4.2 mmHg. Eleven patients had morning
peak (6:00–11:30 am), 8 patients exhibited an
afternoon peak (12:00–5:30 pm) and 10 patients
showed evening peak pressures
(6:00 pm–12:00 am). Fifteen patients (51.7%)
had peak IOP values outside the typical office
hours, and in 14% of them the peak circadian
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IOP was at least 12 mmHg higher than the peak
documented during office hours. Importantly,
circadian IOP measurements led to clinical
management modifications in almost 80% of
patients as a consequence of detecting either
large 24-h IOP fluctuation and/or high IOP
spikes that had not been previously detected in
an office setting. The authors also argued that
the use of Tono-Pen (Reichert, Inc.) in 24-h
IOP monitoring may in fact have
underestimated IOP peaks and fluctuation, as
previous evidence suggests that Tono-Pen may
produce lower values than the gold standard
(Goldmann tonometry) [21]. In a large study
[20] where 3.025 day-and-night IOP profiles
were measured in 1072 eyes of 547 Caucasian
patients with glaucoma, or glaucoma suspects
with Goldmann tonometry, the peak IOP value
was detected at 7:00 am, noon, 5:00 pm,
9:00 pm, and midnight, respectively, in 20.4%,
17.8%, 21.3% 13.9%, and 26.7% of the cases
investigated.
In a 24-h monitoring study performed by
Tajunisah et al. [11], on 202 eyes of open-angle
glaucoma suspects, most of the subjects had
peak readings in the mid-morning
(10:00–11:00 am) and trough readings after
midnight (2:00–3.00 am), with a mean
fluctuation of 6 mmHg. Dinn et al. [45], in a
retrospective chart review, investigated the
concordance of 24-h IOP in fellow eyes of 37
untreated and 56 treated patients with POAG
who were using the same topical medication in
both eyes. The circadian IOP variation was
largely concordant in the fellow eyes of both
groups. The mean difference in IOP change
between fellow eyes over the given time
intervals was found to range from 1.6 to
2.0 mmHg. In the untreated group, peak IOP
occurred at 7:00 am and trough IOP occurred at
09:00 pm, and in the treated group, peak IOP
occurred at 10:00 am without a trend of
decreasing IOP in the course of the day.
Nakakura et al. [46] examined 24-h IOP in 42
patients with POAG treated with combinations
of latanoprost, beta-blockers, and carbonic
anhydrase inhibitors in the sitting position
with a Goldmann tonometer at 3-h intervals.
In this study mean office IOP was similar to
mean 24-h IOP. However, there was no
correlation between office IOP and 24-h IOP
fluctuation, or between office IOP fluctuation
and 24-h IOP fluctuation. Only 6 eyes (8.5%)
showed 24-h IOP fluctuation lower than
3 mmHg. Peak 24-h IOP occurred during office
hours in only 34% of eyes, whereas trough 24-h
IOP occurred during office hours in 72% of eyes.
In the study of Tanaka et al. [47], IOP
measurements at 14 time points (12:00 pm,
3:00 pm, 6:00 pm, 9:00 pm, 12:00 am, 6:00 am,
9:00 am, 12:00 pm, 3:00 pm, 6:00 pm, 9:00 pm,
12:00 am, 6:00 am, and 9:00 am) were
performed over a period of 48 h in 18
untreated POAG eyes and 43 treated POAG
eyes. A nocturnal acrophase pattern with a
remarkable pressure increase at midnight was
observed in treated eyes, although the
non-treated patients group did not show such
an apparent IOP circadian pattern. Among the
different medication groups, a nocturnal
acrophase circadian pattern was observed in
patients being treated by combinations of
prostaglandins and beta-blockers or
prostaglandin analogs, beta-blockers and
carbonic anhydrase inhibitors. However, this
was not apparent in patient groups with single
antiglaucoma medications or the concomitant
use of prostaglandins and carbonic anhydrase
inhibitors.
Liu et al. [22] reported that 24-h IOP was
higher, the diurnal-to-nocturnal change of
habitual IOP was less noticeable, and the
posture-independent IOP pattern around
normal awakening time was different in eyes
Adv Ther (2016) 33:481–517 487
with early glaucomatous changes compared to
healthy eyes. In a multicenter, prospective
study carried out by Quaranta et al. [48],
untreated patients with OHT or POAG
underwent sitting IOP measurements over a
24-h period by Goldmann tonometry and
supine nighttime IOP measurements by
Perkins tonometer. The mean sitting 24-h IOP
was significantly lower than the supine IOP
(22.5 ± 3.7 vs. 23.5 ± 4.3 mmHg; P\0.001).
The mean sitting IOP across the three daytime
points measured was statistically higher than
the sitting IOP across the three nighttime points
measured (23.3 ± 3.4 vs. 21.5 ± 4.0 mmHg;
P\0.001), but was not statistically different
from the mean nighttime supine IOP evaluated
with Perkins tonometry (22.8 ± 4.4 mmHg;
P = 0.07).
Although valuable, it should be
acknowledged that 24-h IOP monitoring
might be impractical or even impossible in
most glaucoma patients. Therefore, the
identification of surrogate measures that may
accurately reflect nocturnal IOP characteristics
is clinically desirable. To address this issue,
Mosaed et al. [49] reviewed 24-h IOP data
collected from 33 younger healthy subjects
(aged 18–25 years), 35 older healthy subjects
(aged 40–74 years), and 35 untreated older
glaucoma patients (aged 40–79 years) housed
in a sleep laboratory and measured in habitual
body position. In all three groups, peak IOP for
each individual occurred for the most part in
the supine position during the nocturnal
period. In older glaucoma patients, significant
correlations were found between average
office-hour sitting IOP and peak nocturnal IOP
(r = 0.601; P\0.001), and between average
office-hour supine IOP and peak nocturnal IOP
(r = 0.713; P = 0.001). In glaucoma patients, the
majority (67%) of the peak 24-h IOP values in
habitual body positions occurred at night.
Using linear regression, the investigators
produced two formulas: peak nocturnal
IOP = 12.04 ? 0.616 9 average office-hour
sitting IOP (r2 = 0.361), and peak nocturnal
IOP = 5.98 ? 0.771 9 average office-hour
supine IOP (r2 = 0.508). The authors suggest
that these formulas may help clinicians predict
peak nocturnal IOP values, based on office-hour
sitting or supine readings in a significant
proportion of older patients with glaucoma.
Diurnal/24-h IOP Control with Medical
Therapy in POAG and OHT
In a meta-analysis of previously randomized,
prospective, crossover or parallel, single or
double-masked trials evaluating the effects of
timolol on diurnal and nighttime IOP and
blood pressure in subjects with POAG and
OHT, a reduction from baseline was observed
for timolol at each time point and for the 24-h
curve (P B 0.009) [50]. Both timolol 0.5% and
timolol hydrogel 0.1% significantly decreased
diurnal, nocturnal, and individual time point
IOP in 24-h period in patients with POAG [51].
Both timolol formulations demonstrated
minimal effects on blood pressure and
calculated diastolic ocular perfusion pressure.
In a 24-h IOP study performed by Feldman
et al. [52], patients with open-angle glaucoma
and OHT insufficiently controlled (IOP
C22 mmHg) on monotherapy were
randomized to either dorzolamide/timolol
fixed combination (DTFC; n = 117) or timolol
(n = 115). Both of the treatments provided
significant IOP reduction over the entire 24-h
measurement period. DTFC exhibited greater
IOP-lowering than timolol during the daytime,
but there was no significant difference at night.
In another study on 1159 subjects with POAG
and OHT, the percentage of patients with mean
diurnal IOP \18 mmHg and daytime IOP
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fluctuation less than 2 mmHg was statistically
significantly higher in the brimonidine/timolol
fixed combination group than in the
brimonidine tartrate 0.2%, or timolol maleate
0.5% groups (P = 0.017) [53]. The
brimonidine/timolol fixed combination and
the concomitant administration of
brimonidine and timolol provided significant
24-h IOP reduction from untreated baseline,
and were statistically equal when compared
directly, at each time point and for the 24-h
pressure curve in patients with POAG and OHT
[54].
Prostaglandin analogs are more potent and
decrease IOP fluctuation more than other
antiglaucoma medications. In a meta-analysis
of randomized clinical trials evaluating the
IOP-lowering effects of commonly used
glaucoma drugs in subjects with POAG and
OHT, relative IOP reductions from baseline were
documented to be: -23% at peak and -20% at
trough for betaxolol 0.5%; -27% at peak and
-26% at trough for timolol 0.5%; -22% at peak
and -17% at trough for dorzolamide 2.0%;
-17% at peak and -17% at trough for
brinzolamide 1.0%; -25% at peak and -18%
at trough for brimonidine 0.2%; -31% at peak
and -28% at trough for latanoprost 0.005%;
-31% at peak and -29% at trough for
travoprost 0.004%; -33% at peak and -28% at
trough for bimatoprost 0.03%; and finally -5%
at peak -5% at trough for the placebo [55]. In
the crossover study by Orzalesi et al. [10], 10
patients with POAG and 10 patients with OHT
were treated with timolol, latanoprost, and
dorzolamide for 1 month in a randomized
sequence. All patients underwent four 24-h
IOP curves: at baseline and after each 1-month
treatment period. IOP measurements were
performed at 3:00 am, 6:00 am, 9:00 am, noon,
3:00 pm, 6:00 pm, 9:00 pm and midnight using
Tono-Pen with the patient supine and sitting,
and a Goldmann applanation tonometer with
the patient sitting at the slit lamp. In this group,
the highest IOP values were measured at
9:00 am and the lowest values at midnight and
3:00 am both in the sitting and supine positions
[10]. Latanoprost was more effective than
dorzolamide and timolol and seemed to lead
to a fairly uniform circadian reduction in IOP.
Timolol was more effective than dorzolamide at
3:00 pm (P = 0.05), whereas dorzolamide
performed better than timolol at midnight and
3:00 am (P = 0.05). In another 24-h study, Liu
et al. [56] compared once-daily timolol and
latanoprost in patients with OHT, or early
glaucomatous changes employing a
pneumotonometer. Sitting and supine
measurements were taken during the 16-h
diurnal period whereas only supine
measurements were taken during the
8-h nocturnal period. In the diurnal period,
the mean IOP in the timolol and latanoprost
treatment periods were significantly less than
the mean untreated IOP in both the sitting and
the supine positions. In contrast, during the
nocturnal period mean supine IOP on timolol
therapy was significantly higher than mean
supine IOP on latanoprost therapy.
The evening administration of latanoprost,
or the combination of latanoprost and timolol
resulted in lower daytime IOP than the morning
dosing of these drugs in patients with POAG
[12, 15]. In a more recent 24-h study, Konstas
et al. [57] compared latanoprost and
preservative-free tafluprost both dosed in the
evening in 38 patients with either POAG or
OHT. This study employed Goldmann
technology (Goldmann tonometer for sitting
IOP at 10:00 am, 2:00 pm, 6:00 pm, and
10:00 pm, and Perkins tonometry for supine
readings at 2:00 am and 6:00 am).
Preservative-free tafluprost demonstrated
similar 24-h efficacy to latanoprost (17.8 vs.
Adv Ther (2016) 33:481–517 489
17.7 mmHg; P = 0.417). Interestingly,
latanoprost demonstrated significantly better
24-h trough IOP (15.9 vs. 16.3 mmHg;
P = 0.041) whereas tafluprost provided
significantly lower 24-h IOP fluctuation (3.2
vs. 3.8 mmHg; P = 0.008) [57].
Latanoprost–timolol fixed combination
decreased IOP more than latanoprost or
timolol monotherapy at each time point and
for the 24-h curve, and demonstrated a
narrower range of IOP fluctuation in patients
with POAG and OHT [58, 59]. Quaranta et al.
[60] showed that both DTFC and latanoprost
0.005% significantly reduced 24-h IOP in
patients with POAG (P\0.0001), but DTFC
achieved lower mean 24-h IOP (15.4 ± 1.9 vs.
16.7 ± 1.7 mmHg; P = 0.004). In agreement
with this study, Konstas et al. [61] investigated
39 patients with POAG and 14 with OHT after 2
and 6 months of therapy and reported almost
similar 24-h efficacy between the DTFC and
latanoprost. In a double-blind, prospective
crossover clinical comparison trial on 36
patients with POAG with insufficiently
controlled IOP despite treatment with
latanoprost monotherapy, the addition of
dorzolamide or timolol led to a significant
lowering of 24-h IOP (P\0.05) [62]. However,
the IOP reduction was greater with the
latanoprost and dorzolamide regimen,
especially at nighttime [62]. In a similar study,
dorzolamide or brinzolamide combined with
latanoprost elicited a significant 24-h IOP
reduction [63]. In the study by Lupinacci et al.
[64], diurnal IOP control between 8:00 am and
8:00 pm was similar in the twice daily versus
three-times daily dosing of dorzolamide as
adjunctive therapy to latanoprost in patients
with POAG, although mean IOP reduction was
significantly lower at 6:00 pm on the
three-times daily regimen of dorzolamide
(4.7 ± 3.3 vs. 2.3 ± 2.7 mmHg; P = 0.038).
Further, brimonidine purite and dorzolamide
added to latanoprost have both been found to
have similar 24-h efficacy and safety in subjects
with POAG or OHT [65].
Katsanos et al. [66] investigated the mean
diurnal fluctuation of patients with OHT,
POAG, or XFG. Based upon 4 measurements
taken between 8:00 am and 8:00 pm diurnal
fluctuation decreased from 6.8 ± 3.2 mmHg at
baseline to 4.0 ± 3.1 and 2.9 ± 1.4 mmHg on
bimatoprost and bimatoprost/timolol fixed
combination, respectively (P\0.05 for both
treatments versus baseline). In another study
by Rossetti et al. [67], bimatoprost was found as
effective as latanoprost/timolol fixed
combination (LTFC) in maintaining 24-h IOP
in patients with glaucoma or OHT switched
from the unfixed combination of latanoprost
and timolol.
In a 24-h study by Seibold and Kahook [68],
IOP measurements were taken using a
pneumotonometer every 2 h in the sitting
position during the 16-h diurnal period and in
the supine position during the 8-h nocturnal
period in 40 subjects with open-angle glaucoma
and OHT. Travoprost with SofZiaTM (Alcon
Laboratories) lowered IOP throughout the
diurnal and nocturnal periods, and increased
ocular perfusion pressure in the diurnal, but not
the nocturnal period. The hypotensive effect
endured for at least 84 h after the last dose. Riva
et al. [28] showed that travoprost uniformly
reduced mean 24-h IOP from 23.4 ± 1.7 mmHg
at baseline to 16.8 ± 2.4 mmHg (28.4%),
16.8 ± 2.5 mmHg (28.1%), 16.8 ± 2.4 mmHg
(28.5%), 16.7 ± 2.5 mmHg (28.6%), and
16.9 ± 2.4 mmHg (27.8%), respectively, at the
end of the first, second, third, fourth, and fifth
year in 36 patients with POAG. In patients with
open-angle glaucoma insufficiently controlled
on travoprost monotherapy, the addition of
brinzolamide/timolol or brimonidine/timolol
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fixed combinations provided clinically
meaningful and statistically significant
incremental 24-h IOP lowering [69]. However,
brinzolamide/timolol fixed combination
obtained significantly better 24-h IOP control
owing to the greater efficacy between 6:00 pm
and 2:00 am [69]. In another meta-analysis
evaluating the IOP-lowering effects of
commonly used fixed combination drugs
containing timolol, the relative reductions for
mean diurnal IOP were found to be 34.9% for
travoprost/timolol, 34.3% for bimatoprost/
timolol, 33.9% for latanoprost/timolol, 32.7%
for brinzolamide/timolol, 29.9% for
dorzolamide/timolol, and 28.1% for the
brimonidine/timolol fixed combinations [70].
IOP Pattern in Exfoliation Syndrome
and XFG
It is worth noting that 24-h IOP characteristics
are generally worse in secondary open-angle
glaucoma (e.g., pigmentary glaucoma and
XFG). Most likely this is a consequence of
intermittent dispersion of pigment and
exfoliation material onto the trabecular
meshwork. Patients with XFG typically exhibit
greater 24-h fluctuation, peak and trough IOP
than patients with POAG [3, 71]. Konstas et al.
[3] have reported a 24-h IOP fluctuation higher
than 15 mmHg in 35% of patients with XFG,
but only in 7.5% of patients with POAG. The
authors documented peak IOP to be outside
office hours (10:00 pm–6:00 am) in almost 45%
of patients with XFG and 22.5% of patients with
POAG [3]. A rhythmic pattern of IOP
fluctuation was seen, with the 10:00 am IOP
measurement yielding the peak IOP value in
both XFG and POAG cohorts, whereas the
lowest mean value for both glaucoma groups
was obtained at 2:00 am [3]. Further, in the
diurnal study by Gumus et al. [72], peak IOP was
also found to be highest in the morning both in
subjects with exfoliation syndrome (XFS) and in
the control group. All in all IOP showed a
gradual decrease from 8:00 am to 6:00 pm in the
control group, whereas a second peak at
3:00 pm was observed only in the XFS group.
Eyes with XFS and high diurnal IOP fluctuation
displayed lower retinal nerve fiber layer
thickness measurements with scanning laser
polarimetry [72]. Huchzermeyer et al. [73]
compared the 24-h IOP profile of 39 eyes with
XFS and 39 matched control eyes and found
that patients with XFS had significantly higher
levels of IOP fluctuation (2.76 ± 1.2 mmHg)
compared with controls (2.2 ± 1.1 mmHg;
P\0.001).
Diurnal/24-h IOP Control with Medical
Therapy in XFG
Timolol 0.5% solution twice daily and timolol
maleate 0.5% gel-forming solution once daily
were both shown to control 24-h IOP in
patients with POAG and XFG in a similar
fashion. However, a trend to lower pressures
was observed in both patients with XFG and
POAG with timolol solution [74]. In a 24-h
study by Konstas et al. [75], 23 patients with
POAG and 11 patients with XFG were
randomized to topical travoprost/timolol fixed
combination (TTFC) administered either in the
morning or evening for a period of 8 weeks. The
IOP was measured at 10:00 am, 2:00 pm,
6:00 pm, 10:00 pm, 2:00 am, and 6:00 am.
Patients were then crossed over to the
alternative dosing regimen for another 8 weeks
and 24-h IOP measurements were repeated. In
untreated patients, the mean IOP was highest at
6:00 am (28.8 ± 4.3 mmHg) and 10:00 am
(29.5 ± 3.2 mmHg), and lowest at 10:00 pm
(26.4 ± 4.5 mmHg) and 2:00 am (25.3 ±
3.8 mmHg). Both dosing regimens reduced IOP
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from baseline at each time-point and for the
mean 24-h curve (P\0.01). However, evening
dosing provided a significantly lower 24-h mean
IOP (18.4 ± 3.3 mmHg) and more narrow IOP
fluctuation (3.8 ± 1.6 mmHg) than the morning
dosing (19.2 ± 3.5 and 5.1 ± 1.6 mmHg,
respectively; P\0.001). In a 24-h study,
Konstas et al. [76] compared the 24-h IOP
control provided by the morning and evening
administration of the bimatoprost/timolol fixed
combination and the evening administration of
bimatoprost in one eye of 60 patients with XFG.
Bimatoprost monotherapy reduced mean 24-h
IOP by 27.8%. The evening administration of
the fixed combination provided superior 24-h
IOP control than the morning administration
(35.3% vs. 33.8%). In their meta-analysis of
24-h IOP fluctuation studies and the efficacy of
glaucoma medicines, Stewart et al. [77]
established that bimatoprost demonstrates the
greatest reduction in 24-h fluctuation
(3.4 mmHg) among various glaucoma
treatments (P = 0.03) and reported that
patients with XFG generally demonstrate a
greater decrease in fluctuations than patients
with POAG (P = 0.003).
Diurnal/24-h Fluctuation and Glaucoma
Progression
The potential detrimental role of large IOP
fluctuations in the development or progression
of glaucoma has received increasing attention
[8, 25, 78–83]. Based on the concept that large
diurnal IOP fluctuation and high peak IOP may
be harmful to the glaucomatous optic nerve,
many clinicians now feel that optimal
glaucoma therapy should aim to minimize the
circadian IOP fluctuation and to eliminate as
much as possible the pressure spikes [9].
However, it is uncertain as yet which 24-h IOP
parameter (peak, mean, or fluctuation) is more
important in disease progression. Barkana et al.
[84] performed a chart review of 32 patients
with open-angle glaucoma whose office IOP
readings did not seem to explain the severity or
glaucomatous progression. All patients were
medically treated or had undergone laser
trabeculoplasty and/or trabeculectomy.
Pressure monitoring was carried out
employing Goldmann tonometry in the sitting
position from 7:00 am until midnight and
Perkins tonometry in the supine position at
6:00 am. Peak IOP was detected outside of office
hours in at least one eye in nearly 70% of their
patients. Peak 24-h IOP was higher than that
recorded in the office in 62% of cases and mean
IOP fluctuation during 24-h monitoring
(6.9 ± 2.9 mmHg) was significantly greater
than that measured during office hours
(3.8 ± 2.3 mmHg; P\0.001). The results of
this 24-h IOP monitoring study led to
immediate treatment change in at least one
eye of almost 60% of study patients. In the
study of Asrani et al. [8], the diurnal IOP range
of 5 measurements obtained in a day using
home tonometry and the IOP range over 5 days
were found to be significant risk factors for
progression in 105 eyes of 64 patients with
open-angle glaucoma. However, this study has
raised some methodological issues and no study
since has replicated this research approach. In
another study by Bergea et al. [25], diurnal IOP
measurements and automated visual field tests
were performed in 76 patients for 2 years, the
majority of whom had XFG and both mean IOP
and IOP variation (range and peak) were found
to be significant predictors of glaucoma
progression.
In the study by Wilensky et al. [78], more
than half of the patients with glaucoma
investigated had one or more IOP readings
above 22 mmHg with self-tonometry applied 5
times a day between awakening and bedtime for
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3 to 6 days, although they had an IOP of
22 mmHg or less at 3 consecutive visits before
recruitment into the study. Moreover, the peak
IOP was measured either before 8:00 am or after
5:00 pm in nearly half of these cases, which
means they were unlikely to have been detected
in a routine office visit. More elevated IOP
readings were recorded in patients with
suspected or documented progression of
glaucomatous damage than in patients
thought to be stable or in normal subjects. In
the diurnal study conducted by Thomas et al.
[79], mean IOP fluctuation was found to be
8.6 mmHg in subjects with OHT that later
converted to POAG, as compared to only
5.4 mmHg in the group that did not convert
to glaucoma. After 5 years, 4 of 23 patients with
OHT had converted to POAG. Thus, the 5-year
incidence of POAG amongst subjects with OHT
was 17.4% (95% CI 1.95–32.75), or 3.5% per
year. The relative risk of conversion amongst
patients with OHT was 19.1 (95% CI 2.2–163.4).
Bilateral OHT, higher peak IOP, and large
diurnal variation were shown to be the risk
factors for conversion. In the diurnal study of
Gonzalez et al. [80] which included 149 subjects
with OHT, 82% of cases with a flat diurnal curve
preserved their normal visual field, whereas
64% of cases with an IOP fluctuation greater
than 5 mmHg developed a glaucomatous visual
field defect within a follow-up period of 4 years
(P\0.05).
In contrast, a study performed by Jonas and
coworkers [81] did not find a relationship
between diurnal IOP fluctuation and
glaucomatous progression. This study relied on
sitting Goldmann measurements performed at
7:00 am, noon, 5:00 pm, 9:00 pm, and
midnight obtained from 458 Caucasian
patients with chronic open-angle glaucoma or
OHT [81]. The authors concluded that, while
mean IOP exerts a significant influence upon
the rate of glaucomatous progression, IOP




Clinical management of a patient with
glaucoma is primarily based on establishing an
individual target IOP that can vary depending
upon parameters such as age, visual field
damage, rate of progression, baseline IOP, and
overall risk profile. Treatment options must be
selected so that target IOP is attained
considering 24-h drug efficacy. The following
section presents clinical efficacy data of
antiglaucoma drug classes as highlighted by
key published studies.
Prostaglandin Analogs
Prostaglandins are currently the most potent
topical antiglaucoma medications, achieving a
mean 24-h IOP reduction of 24–29% [6, 85].
Their efficacy appears to be fairly uniform
throughout the circadian cycle [6], although
24-h studies generally have demonstrated that
the peak efficacy of all prostaglandins occurs
8–12 h after administration [10, 12, 15, 17, 76].
Published evidence indicates that prostaglandin
efficacy is greater during the morning/daytime
with evening dosing [12, 27, 77]. All
prostaglandins are thought to exert their
ocular hypotensive effect by increasing the
uveoscleral (and to a lesser extent the
trabecular) outflow of aqueous [86]. Their
superior 24-h efficacy profile and their
convenient dosing (once daily, mostly in the
evening) have made prostaglandins a popular
first-choice glaucoma therapy.
Latanoprost, the first member of this class
became commercially available in 1996. It is a
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prostaglandin F2a isopropyl ester pro-drug,
which is rapidly hydrolyzed by esterases in the
cornea to the biologically active latanoprost
acid [87]. Its efficacy has been extensively
compared with other commonly used
glaucoma medications. Orzalesi and coworkers
[10] evaluated the 24-h IOP reduction achieved
with latanoprost in POAG and OHT. They
established that latanoprost was more
efficacious in lowering IOP than the prototype
beta-blocker timolol at 3:00 am, 6:00 am,
9:00 am, 12:00 am, 9:00 pm, and at midnight.
It was also more effective than the topical
carbonic anhydrase inhibitor dorzolamide at
9:00 am, noon, 3:00 pm, and 6:00 pm.
Quaranta et al. [85] reported similar results:
latanoprost was more efficacious than timolol
from 10:00 pm to 6:00 am. No significant
differences in IOP were found for the period
between 8:00 am and 8:00 pm between timolol
and latanoprost, while dorzolamide was as
effective as latanoprost during the night from
10:00 pm to 6:00 am.
The peak efficacy of latanoprost remains a
matter of debate and may differ from patient to
patient, but is generally thought to occur
approximately 8–12 h after administration [12,
88]. In a 6-month randomized, double-masked,
multicenter study with three parallel groups
(latanoprost dosed either in the morning or
evening and timolol), Alm and Stjernschantz
[89] showed that timolol reduced the mean
diurnal IOP from 24.6 to 17.9 mmHg (27%),
morning-dosed latanoprost from 25.5 to
17.7 mmHg (31%) and evening-dosed
latanoprost from 24.8 to 16.2 mmHg (35%).
The efficacy of evening-dosed latanoprost was
statistically superior to morning-dosed
latanoprost and to timolol (P\0.001). The
24-h efficacy of morning versus evening
administration of latanoprost was compared in
a crossover study by Konstas et al. [12]. These
authors reported that both regimens were
efficacious over the 24 h, but evening
administration provided a statistically lower
IOP at 10:00 am, while morning
administration provided a statistically lower
pressure at 10:00 pm. At the critical 6:00 am
time-point, when IOP is often high in patients
with glaucoma, both dosing regimens were
equally efficacious. On the basis of this
pattern, clinicians may select the optimal time
of administration depending on each patient’s
circadian IOP profile. However, since evening
dosing induced lower 24-h IOP fluctuation
compared with morning administration
(4.4 ± 1.8 vs. 5.7 ± 2.4 mmHg) evening
administration may be preferable in most
patients.
In an 8-week treatment, prospective,
crossover, double-masked comparison, Konstas
et al. [90] evaluated the quality of 24-h IOP
control between morning- and evening-dosed
travoprost in patients with POAG. The
untreated mean circadian IOP was
23.6 ± 2.0 mmHg. There were no differences
for mean 24-h IOP between the morning
(17.5 ± 1.9 mmHg) and evening
(17.3 ± 1.9 mmHg) dosing (P = 0.7). At
10:00 am, the evening dosing provided a
statistically lower IOP (17.2 ± 2.1 mmHg) than
the morning dosing (19.1 ± 2.5 mmHg;
P = 0.02). Evening dosing demonstrated a
statistically lower 24-h fluctuation of IOP
(3.2 ± 1.0 mmHg) than morning dosing
(4.0 ± 1.5 mmHg; P = 0.01). This study
suggests that both morning and evening
dosing of travoprost provide effective 24-h IOP
reduction. However, the evening dosing of
travoprost demonstrates slightly greater
daytime efficacy, with a narrower range of
24-h pressure.
The relative 24-h efficacy of each
prostaglandin analog has been the subject of
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intense investigation. The first head-to-head,
parallel arms, daytime comparison between
latanoprost, bimatoprost and travoprost was
conducted by Parrish et al. [91]. In this
investigation, neither the magnitude nor the
pattern of daytime IOP reduction was
statistically different in the three
prostaglandin groups. Furthermore, a trial by
Orzalesi et al. [92] compared the 24-h efficacy of
latanoprost, travoprost, and bimatoprost in
patients with POAG and OHT: all 3
prostaglandins appeared similarly effective in
controlling 24-h IOP with greater efficacy seen
during the daytime than at night. In another
crossover 24-h study, Konstas et al. [18]
evaluated evening-dosed latanoprost and
bimatoprost in patients with POAG and
reported that 24-h efficacy was statistically
better with bimatoprost than latanoprost,
although the overall IOP difference between
groups was small. In a parallel arms study,
Yildirim et al. [93] randomized 48 patients with
newly diagnosed open-angle glaucoma to
treatment with latanoprost (n = 17), travoprost
(n = 15), and bimatoprost (n = 16) over 8 weeks.
The mean untreated 24-h IOP for the groups
were 22.3 mmHg, 23.4 mmHg, and 22.6 mmHg,
respectively (P[0.05). Although the mean 24-h
treated IOP for each group is not reported, the
authors mention that in patients treated with
travoprost, IOP was reduced by 8.7 and
8.1 mmHg at the 08:00 am and 10:00 am time
points, respectively. At the same time points,
patients treated with latanoprost demonstrated
smaller IOP reductions (4.8 and 5.3 mmHg,
respectively). Patients treated with bimatoprost
also exhibited less IOP reduction (5.5 and
4.9 mmHg) than with travoprost. Pressure
differences at all other time points were not
statistically significant. According to this
investigation, IOP reduction at 8:00 am and
10:00 am in the travoprost group was
significantly greater that with the other two
prostaglandins. In contrast to these results, a
diurnal study by Gandolfi et al. [94] showed
that bimatoprost was superior to latanoprost at
two time points, noon and 4:00 pm. In another
diurnal study by DuBiner et al. [95],
bimatoprost provided a greater mean
reduction in IOP than latanoprost at all time
points during the day (8:00 am, noon, 4:00 pm,
and 8:00 pm) after one month of treatment.
More recently, the circadian ocular
hypotensive effect of travoprost with the
SofZia preservative was reported [68]. In a
prospective, open-label study performed in a
sleep lab with 40 participants with open-angle
glaucoma or OHT, it was shown that travoprost
significantly lowered mean diurnal and
nocturnal IOP levels from baseline after
1 month of therapy. Moreover, the
investigators examined the maintenance of
the ocular hypotensive effect after three
travoprost doses were omitted. They found
that mean IOP remained significantly lower
than baseline both during the daytime and
nighttime. It is worth noting that in this study,
travoprost reduced only modestly daytime IOP
(16%), nighttime IOP (6%), and mean 24-h IOP
(12%) in the habitual position. This may be
attributed to the relatively low baseline pressure
(sitting daytime IOP: 18.1 ± 3.9 mmHg, supine
nighttime IOP: 20.6 ± 3.6 mmHg).
A recent crossover study compared the 24-h
efficacy of preservative-free tafluprost versus
branded, preserved latanoprost in patients
with POAG or OHT [57]. Both medications
significantly reduced the untreated mean IOP
(24.9 mmHg). When directly compared,
preservative-free tafluprost exhibited similar
mean 24-h efficacy with latanoprost
(17.8 vs. 17.7 mmHg; P = 0.417). In this study,
latanoprost demonstrated significantly lower
24-h trough pressure (15.9 vs. 16.3 mmHg;
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P = 0.041) whereas preservative-free tafluprost
provided significantly lower 24-h fluctuation
(3.2 vs. 3.8 mmHg; P = 0.008).
Although in general the reported 24-h
efficacy of prostaglandins is clinically
comparable, some data suggest that travoprost
and bimatoprost may provide more consistent
IOP reduction over the 24-h period [6].
Specifically, travoprost has been shown to be
more effective than latanoprost [96] and overall
travoprost and bimatoprost appear to reduce
nighttime IOP more consistently than
latanoprost [68, 96–98]. Therefore, patients on
travoprost or bimatoprost may be more likely to
achieve a lower target 24-h pressure [6, 55, 99].
Although it remains to be established if such
statistically significant 24-h IOP differences are
also clinically meaningful, controlled trials
employing single pressure measurements have
shown that 1 mmHg of further IOP reduction
can reduce the risk of glaucoma progression by
approximately 10% [100, 101]. Taking these
facts in account, it can be assumed that there is
even more value in maintaining a lower target
IOP over the full 24-h period.
Recently, Tung et al. [102], in a sleep
laboratory study, investigated the 24-h efficacy
of the recently available 0.01% bimatoprost
solution in a cohort of patients with either
POAG (n = 3) or OHT (n = 13). In contrast to
the standard 0.03% bimatoprost solution, the
new formulation was developed with the aim of
reducing the occurrence and severity of ocular
hyperaemia while broadly maintaining the
efficacy of the 0.03% solution. To achieve this,
the 0.01% formulation had to contain a higher
concentration of the preservative benzalkonium
chloride compared to the standard 0.03%
bimatoprost formulation (0.2 vs. 0.05 mg/mL).
This was deemed necessary to enhance corneal
penetration and intraocular bioavailability of
the new formulation. Although the authors do
not report the mean 24-h efficacy of the study
medication, they demonstrate a mean habitual
IOP reduction of 21.7% during the day and
10.2% during the night.
There is generally limited information on the
24-h efficacy of prostaglandins in other
glaucomas. Ishibashi et al. [103] investigated
the effect of latanoprost on circadian sitting IOP
in patients with NTG. They found that
latanoprost offered a statistically significantly,
but relatively small, mean 24-h IOP reduction
(12.5%) in this series of patients with relatively
low baseline IOP (mean IOP at baseline:
13.9 mmHg). In a crossover,
investigator-masked 24-h study with newly
diagnosed, previously untreated patients with
NTG, evening-dosed latanoprost and
bimatoprost exhibited similar efficacy over the
24-h period (16% reduction from baseline) and
for each time-point measured [104]. A crossover
study by Costagliola et al. [105] showed that the
24-h efficacy of latanoprost is superior to that of
timolol 0.5% dosed twice daily in patients with
NTG.
Considering the chronic, insidious nature of
glaucomatous damage and the possibility that
suboptimal long-term IOP control may increase
the chances of disease progression [30, 83, 84],
knowledge of the long-term 24-h efficacy of all
medications should be considered highly
relevant. Topical therapy for glaucoma should
be effective in maintaining a sustained IOP
reduction over the long-term [106, 107].
Clinical trials with latanoprost monotherapy
have established a long-lasting daytime
hypotensive effect with little evidence of
tachyphylaxis for up to 4 years [106–110].
Recently, a 24-h investigation by Riva et al.
[28] showed that a relatively high proportion
(82%) of previously untreated patients with
POAG reached and maintained a
predetermined, individualized target IOP
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reduction between 20 and 30% with travoprost
monotherapy during a 5-year follow-up period
that included annual 24-h measurements. This
long-term result compares well with the
reported short-term 24-h efficacy of travoprost
monotherapy [6]. Similarly, a multicenter study
on patients with POAG treated with latanoprost
monotherapy reported satisfactory IOP control
in the vast majority of their patients (86%), but
this was with a shorter 2-year follow-up [111].
Timolol Maleate
To date there has been very little published 24-h
evidence on other beta-blockers, except timolol
maleate. Timolol is a beta-adrenergic blocker
that has been used as an IOP-reducing
medication since 1979. Currently, it is
available both as a hydrogel formulation (0.1%
or 0.5%) administered once daily and an
ophthalmic solution (0.25% or 0.50%)
typically administered twice daily.
In a 24-h study, Konstas et al. [7] investigated
the efficacy of timolol over 24 h and reported a
mean circadian efficacy ranging from 10% to
25% in patients with POAG. In a subsequent
24-h study, Orzalesi et al. [10] evaluated the
ocular hypotensive effect of timolol in patients
with POAG and OHT and established that the
nocturnal efficacy was only about half the
daytime efficacy. Quaranta et al. [85]
consolidated previous evidence and also
documented a greater daytime IOP reduction
and a smaller, yet still significant, nighttime
reduction with timolol. In contrast, Liu et al.
[56] compared the efficacy of once-daily timolol
gel-forming solution and latanoprost and found
that latanoprost, but not timolol, reduced the
nocturnal IOP in patients with early glaucoma
or OHT. In that study both medications
demonstrated similar daytime efficacy. Timolol
0.5% solution has been shown to achieve a
mean 24-h IOP reduction of between 19% and
24% from untreated baseline [6, 85]. Although
its efficacy tends to be reduced at nighttime,
cumulative evidence suggests that its ocular
hypotensive effect persists clinically throughout
the 24-h cycle [6, 7, 10, 50, 51, 74, 85, 112]. As
beta-blockers exert their ocular hypotensive
effect by reducing aqueous humor production,
the weaker nocturnal efficacy of timolol has
been attributed to the lower rate of aqueous
synthesis at night [113, 114].
Timolol gel-forming solutions have been
developed in an attempt to extend the
duration of its action allowing for once-daily
administration, while at the same time
improving the systemic safety profile of
timolol. Moreover, potential clinical
advantages of once-daily timolol gel
instillation may include enhancement of
adherence and reduced exposure to
preservatives. A multicenter daytime study by
Shedden et al. [112] compared the efficacy and
tolerability of 0.5% timolol maleate ophthalmic
gel-forming solution and 0.5% timolol
ophthalmic solution in adults with POAG or
OHT. In this trial, IOP measurements were
performed at trough (before the morning
instillation) and peak (2 h after instillation)
efficacy. The gel-forming solution administered
once daily in the morning was just as efficacious
as the timolol ophthalmic solution administered
twice daily. In a subsequent complete 24-h
assessment of the two formulations, Konstas
et al. [74] reported similar 24-h efficacy in
previously untreated patients with either POAG
or XFG. This observation was further supported
in a crossover study with naive patients with
POAG conducted by Quaranta et al. [51], who
documented comparable 24-h efficacy between
twice-daily timolol 0.5% solution and timolol
0.1% ophthalmic gel administered in the
morning.
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Topical Carbonic Anhydrase Inhibitors
This class of medications comprises two drugs
with virtually identical efficacy and tolerability
profiles, namely dorzolamide hydrochloride 2%
solution and brinzolamide 1% suspension
[115–117]. Dorzolamide hydrochloride 2% was
the first topical carbonic anhydrase inhibitor to
become commercially available in 1995 for the
treatment of POAG or OHT. It has been reported
to reduce IOP from 16% to 26% as
monotherapy when dosed three-times daily [6,
10, 85, 118, 119]. Subsequently, a number of
24-h efficacy studies have shown that contrary
to timolol, dorzolamide is more efficacious
during the night. First, Orzalesi et al. [10]
compared dorzolamide, timolol and
latanoprost in a 24-h IOP trial and found that
mean IOP was significantly lower with
latanoprost whereas there was no significant
difference between dorzolamide and timolol
with regard to mean 24-h IOP. They also
reported that dorzolamide was more
efficacious than timolol during the night
(midnight and 3:00 am), while latanoprost did
lower nighttime IOP more than dorzolamide. In
another 24-h investigation [13], dorzolamide
was added to timolol in patients with POAG or
XFG chronically treated with timolol; following
the addition of dorzolamide as adjunctive
therapy to timolol maleate there was a
significant reduction in IOP (P\0.05) at all
time points. Contrary to the report by Orzalesi
et al. [10], a report by Quaranta et al.
documented dorzolamide to be as effective as
latanoprost during nighttime (10:00 pm to
6:00 am) and less effective than timolol or
latanoprost during daytime (6:00 am to
8:00 pm) [85].
A meta-analysis by Stewart et al. [6]
confirmed the observation that carbonic
anhydrase inhibitors may be the only class of
medications with better nighttime than
daytime efficacy. Specifically, this
meta-analysis reported that dorzolamide
reduced mean IOP by 16% at daytime and
21% at nighttime. The enhanced nighttime
efficacy of dorzolamide contrasts to the
reduced nighttime efficacy of timolol. This
characteristic dissimilarity may be attributed
to the different mode of action of these
medications: although both exert their ocular
hypotensive effect by reducing the synthesis of
aqueous humor, dorzolamide does so by
inhibiting the activity of carbonic anhydrase,
while timolol blocks beta-adrenergic receptors
[118]. The normally occurring reduction in
endogenous circulating catecholamines at
night may explain the decreased nocturnal
efficacy of beta-blockers [120]. Vanlandingham
et al. [119] evaluated the effect of dorzolamide
on aqueous humor dynamics in normal subjects
during sleep using a fluorophotometry
technique and observed that dorzolamide
suppressed nighttime flow in the sleeping eye
by only 9%, which is significantly less than the
nighttime effect of acetazolamide (24%
suppression).
A daytime comparison of twice-daily versus
three-times-daily administration of
dorzolamide as adjunctive therapy to
prostaglandins was performed by Lupinacci
et al. [64]. The two regimens were equally
efficacious, except for a single time-point at
6:00 pm where the three-times-daily dosage
offered a significantly lower IOP (-4.7 vs.
-2.3 mmHg).
Brimonidine
Brimonidine 0.2% was released commercially in
late 1996. It is a highly selective a2-adrenergic
agonist. Similarly to dorzolamide, it is labeled
for use three-times a day, but it may be
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administered twice daily. Brimonidine 0.2%
dosed twice daily achieves a mean 24-h IOP
reduction of 14% to 19% [6, 86, 121]. Quaranta
et al. [85] reported that the 24-h IOP reduction
pattern with brimonidine was similar to
dorzolamide at daytime (8:00 am to 8:00 pm)
and to timolol at nighttime (10:00 pm to
6:00 am). However, in another 24-h crossover
study, Orzalesi et al. [21] documented
brimonidine to have minimal efficacy during
the late nighttime and early morning period
(3:00 am and 6:00 am) with no significant IOP
difference from untreated baseline. This
reduced nighttime hypotensive efficacy was
comparable to that reported for timolol [14,
122]. Furthermore, Liu et al. [123] in an
open-label 24-h study performed in a sleep
laboratory with 15 patients with open-angle
glaucoma or OHT, observed that brimonidine
given three-times daily reduced the mean
daytime IOP by 12.5% but had no
demonstrable IOP-lowering effect during the
night.
In a crossover double-masked trial, Konstas
et al. [14] evaluated the 24-h efficacy of
brimonidine 0.2% administered twice, or
three-times daily versus timolol maleate 0.5%
given twice daily in patients with POAG. The
mean 24-h IOP for brimonidine twice daily and
three-times daily was 19.2 mmHg and
18.0 mmHg, respectively, whereas for timolol
it was 17.7 mmHg. The differences for all 24-h
comparisons were significant. Moreover,
pair-wise comparisons showed that thrice-daily
brimonidine or twice-daily timolol reduced IOP
more than twice-daily brimonidine at every
time point after 10:00 am. In contrast,
thrice-daily brimonidine and twice-daily
timolol were statistically similar over the 24-h
period, except at 4:00 pm when timolol maleate
performed significantly better. This group of
investigators also reported that
three-times-daily brimonidine provided
significantly better late afternoon and early
nighttime efficacy than twice-daily dosing. In
a subsequent double-masked, crossover
multicenter daytime study, Stewart et al. [121]
compared brimonidine 0.2% versus
dorzolamide 2% both administered three-times
daily, and found similar mean IOP reduction at
both trough and peak efficacy time points.
Similar results were reported in a
double-masked crossover diurnal study by
Whitson et al. [124].
24-H EFFICACY OF FIXED
AND UNFIXED COMBINATION
THERAPIES
Cumulative evidence from clinical trials clearly
indicates that the majority of glaucoma patients
need more than one medication to reach target
IOP. The Collaborative Initial Glaucoma
Treatment Study (CIGTS) found that about
75% of patients needed 2 or more medications
to reach the predetermined target pressure
[125]. Compared to concomitant
administration of glaucoma medications, fixed
combinations offer several potential advantages
such as ease of use, decreased exposure to
preservatives, improved adherence and
avoidance of medication washout [126].
Several studies have compared the efficacy and
safety of fixed combinations versus
monotherapies, or the concomitant use of
individual medications. Unfortunately, most
published studies have assessed the diurnal
efficacy of fixed combinations, with a few
daytime IOP measurements, rather than the
complete 24-h efficacy.
This section summarizes the existing
evidence on the 24-h ocular hypotensive effect
of both fixed and unfixed combinations.
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Pilocarpine containing combinations were not
reviewed. As evidenced in the following
paragraphs, very few trials were carried out
with the primary objective of evaluating the
24-h efficacy of unfixed combinations, except
when comparisons with fixed combinations
were made. Similarly, although there are few
systematic reviews and meta-analyses that have
examined the efficacy of combination therapies
in glaucoma [70, 127, 128], only one has
specifically focused on 24-h efficacy [6] and
another on 24-h IOP fluctuation [77].
Combinations of Prostaglandin Analogs
with Beta-Blockers
Combination of Latanoprost and Timolol
A meta-analysis of clinical trials on the 24-h
efficacy of IOP-lowering medications reported
an average reduction of 33% for the LTFC [6].
A placebo-controlled crossover study was
carried out in 20 patients with OHT with a
follow-up of 1 month [20]. The LTFC was more
efficacious than placebo in reducing 24-h IOP:
the ocular hypotensive effect was in favor of
LTFC both at daytime (10:00 am to 10:00 pm)
and at nighttime (5.6 and 3.1 mmHg,
respectively).
In a 2-month, crossover trial, Konstas et al.
[58] compared the circadian efficacy of timolol
dosed twice daily and LTFC dosed in the
evening in 34 patients with POAG. Pressure
was measured every 4 h in the sitting position
with a Goldmann tonometer. LTFC was more
efficacious than timolol at all time points. Mean
IOP was reduced from 25 mmHg at baseline to
16.4 and 19.3 mmHg with LTFC and timolol,
respectively. These results were later confirmed
in a similar crossover 24-h IOP and blood
pressure trial investigating LTFC and timolol
in eyes with POAG or OHT [129]. The 24-h
efficacy of LTFC compared with that of
latanoprost when both medications are
administered in the evening was investigated
in a 2-month crossover trial in a group of 37
patients with POAG [19]. The sitting IOP was
measured with a Goldmann tonometer every
4 h. The baseline IOP was reduced from 24.2 to
16.7 mmHg and 19.2 mmHg with LTFC and
latanoprost, respectively. Both the mean and
the individual time point IOP reduction were
significantly lower with LTFC. A 3-month,
parallel arms, randomized clinical trial
investigated the efficacy of LTFC given in the
morning and bimatoprost given at night over a
period of 24 h [67]. These investigators reported
that both regimens were equally efficacious in
reducing 24-h IOP and no significant difference
was detected in mean diurnal or nocturnal
pressures.
Combination of Travoprost and Timolol
In a 4-month crossover study, the efficacy of
morning versus evening administration of TTFC
was compared in 32 patients with either POAG
or XFG [75]. The IOP was measured with
Goldmann tonometry. Mean baseline 24-h IOP
was 27.7 mmHg and both morning and evening
dosing of the TTFC resulted in a highly
significant IOP reduction at all time points.
Compared to morning dosing, the evening
dosing of TTFC was associated with
significantly lower 24-h IOP
(18.4 vs. 19.2 mmHg) and reduced 24-h
fluctuation (3.8 vs. 5.1 mmHg). More recently,
the 24-h efficacy of LTFC preserved with
benzalkonium chloride and TTFC preserved
with Polyquad (Alcon Laboratories) when
both are administered in the evening was
compared in glaucoma patients insufficiently
controlled with latanoprost monotherapy [130].
In this observer-masked, crossover, 3-month
study, the investigators employed Goldmann
and Perkins tonometers to evaluate 42 patients
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with open-angle glaucoma chronically treated
with latanoprost who exhibited daytime IOP
[20 mmHg on two separate occasions. The
mean latanoprost-treated baseline IOP was
21.5 ± 1.6 mmHg. Both fixed combinations
significantly reduced the IOP at each
time-point, as well as the mean, peak, and
24-h IOP fluctuation. However, the TTFC
preserved with Polyquad provided significantly
lower mean 24-h IOP (18.9 ± 2.2 vs.
19.3 ± 2.3 mmHg; P = 0.004) and significantly
lower IOP at 6:00 pm (18.6 ± 2.5 vs.
19.5 ± 2.7 mmHg; P\0.001).
Combination of Bimatoprost and Timolol
Konstas et al. [76] evaluated the efficacy of the
fixed combination of bimatoprost and timolol
(BTFC) on 24-h IOP. These investigators
included 60 patients with XFG in a three-arm,
crossover trial. The mean untreated baseline
IOP was 29.0 mmHg. Patients were first treated
with bimatoprost monotherapy for 6 weeks and
were then randomized to morning, or evening
administration of BTFC for another 3 months.
Compared to morning dosing, evening dosing
of BTFC was statistically more efficacious: the
mean 24-h IOP reduction with evening versus
morning dosing was 10.2 and 9.8 mmHg,
respectively (P = 0.005). Both morning and
evening dosing of BTFC was more efficacious
than bimatoprost monotherapy at all time
points. In a more recent investigator-masked,
crossover, 3-month trial, the 24-h efficacy of
evening-dosed BTFC was investigated as
first-choice therapy compared with a standard
first-choice therapy (latanoprost) in 37 patients
with high-pressure XFS or XFG [131]. The mean
untreated 24-h IOP was 31.1 mmHg. At the end
of the 3-month period BTFC reduced mean 24-h
IOP significantly more than latanoprost (18.9
vs. 21.2 mmHg; P\0.001). Additionally, BTFC
was significantly more efficacious than
latanoprost at every time point for the mean
peak and trough 24-h pressure (P\0.001).
Combinations of Carbonic Anhydrase
Inhibitors with Beta-Blockers
Combination of Dorzolamide and Timolol
A meta-analysis of clinical trials on the 24-h
efficacy of IOP-lowering medications reported
an average reduction of 26% with the DTFC
compared to baseline [6]. It is noteworthy that
to date several investigators have evaluated the
24-h efficacy of DTFC. A parallel arms,
randomized, 2-month trial compared DTFC
with timolol in a large cohort of 232 patients
with open-angle glaucoma or OHT [52]. DTFC
significantly reduced IOP at all time points
when compared to baseline. Compared to
timolol monotherapy, DTFC therapy resulted
in a statistically significant lower mean daytime
IOP and at two time points: 10:00 am and
2:00 pm.
In a 6-week crossover study of patients with
POAG and OHT, Konstas et al. [16] compared
the 24-h efficacy of latanoprost versus DTFC.
The mean circadian IOP for latanoprost and
DTFC was 15.9 ± 2.3 and 15.3 ± 2.0 mmHg,
respectively (P = 0.05). Although there was no
significant IOP difference at other time-points,
at the 10:00 am time-point pressures with
latanoprost and DTFC were 16.6 ± 3.1 and
14.6 ± 2.7 mmHg, respectively (P\0.006).
Quaranta et al. [60], in a 3-month crossover
trial, compared the 24-h efficacy of DTFC and
latanoprost in a group of 27 previously
untreated patients with POAG. The authors
found a significant difference in mean
circadian IOP reduction between treatments
(1.3 mmHg) in favor of DTFC when the fixed
combination was employed as first-choice
therapy. Konstas et al. [61] compared the
short-term versus the mid-term 24-h efficacy
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of DTFC and latanoprost in a six-month
crossover study that included 53 patients with
POAG or OHT. The mean 24-h baseline IOP
(25.2 mmHg) was reduced to 18.1 mmHg and
18.3 mmHg with DTFC and latanoprost,
respectively. With the exception of one
time-point (10:00 am), this study documented
similar 24-h efficacy between the two
medications at 2 and 6 months.
In another crossover study, Orzalesi et al.
[21] investigated the circadian IOP
characteristics of 20 patients with POAG or
OHT who were treated with DTFC, latanoprost,
or brimonidine. This study documented greater
efficacy for DTFC compared with brimonidine
at 3:00 am, 9:00 am, 3:00 pm, and 6:00 pm.
Furthermore, DTFC was also more efficacious
than latanoprost at 9:00 am. Eren et al. [132]
conducted a double-masked, 6-week, crossover
24-h study employing Goldmann tonometry to
compare DTFC and LTFC in 33 washed-out
POAG patients. The mean untreated 24-h IOP
was 25.1 mmHg. In this study, LTFC was more
efficacious than DTFC in lowering the mean
24-h IOP (16.3 vs. 17.3 mmHg) and the peak
24-h IOP (18.5 vs. 19.9 mmHg).
The 24-h IOP-lowering effect of DTFC was
compared to that of the timolol–brimonidine
fixed combination in a crossover trial [133].
DTFC was more effective and the difference
(mean -0.7 mmHg; 95% CI -1.0 to -0.3;
P\0.001) reached statistical significance.
Combination of Brinzolamide and Timolol
There is limited information available on the
24-h efficacy of the brinzolamide/timolol fixed
combination. Recently, the 24-h IOP reduction
obtained with the brinzolamide/timolol and the
brimonidine/timolol fixed combination as
adjunctive therapies to travoprost was
investigated in an observer-masked, crossover
24-h study in patients with POAG and XFG
insufficiently controlled with travoprost [69].
These authors found that the
brinzolamide/timolol fixed combination
provided significantly better mean 24-h IOP
control (17.2 mmHg) than the
brimonidine/timolol fixed combination
(18.0 mmHg). In particular, the
brinzolamide/timolol fixed combination
provided superior IOP control in late
afternoon and in the night (6:00 pm till
2:00 am; P B 0.036).
Combinations of Carbonic Anhydrase
Inhibitors with a Prostaglandin Analog:
Dorzolamide/Brinzolamide
and Latanoprost
Three studies have examined the 24-h efficacy
of dorzolamide when added to latanoprost.
Tamer et al. [62] conducted a crossover trial
with 36 patients with POAG treated with
latanoprost monotherapy and found an
additional ocular hypotensive effect of
3.2 mmHg over 24 h when dorzolamide was
added to latanoprost. Timolol was less effective
over 24 h when added to latanoprost
(2.6 mmHg). Importantly, when all time
points were analyzed in this trial, dorzolamide
was superior to timolol in five out of the eight
time points evaluated. In a crossover trial,
Nakamura et al. [63] compared the adjunctive
24-h efficacy of dorzolamide versus that of
brinzolamide when both are added to
latanoprost. Compared to the latanoprost
baseline, both carbonic anhydrase inhibitors
resulted in a significantly reduced IOP. No
difference in efficacy between the two drugs
could be established. Finally, a crossover study
by Konstas et al. [65] examined the 24-h
IOP-lowering effect of dorzolamide or
brimonidine purite when added to
latanoprost. Mean latanoprost-treated
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circadian IOP (19.0 mmHg) was further reduced
to 16.9 mmHg and 16.8 mmHg with
brimonidine purite and dorzolamide,
respectively.
Combination of an Alpha-2 Agonist
and a Beta-Blocker: Brimonidine
and Timolol
To date there is limited 24-h IOP evidence for
the combination of brimonidine and timolol in
patients with glaucoma. A 6-month crossover
study has evaluated the 24-h IOP-lowering
effect of the fixed combination of brimonidine
and timolol versus the concomitant
administration of the 2 components in a
cohort of 28 patients with POAG or OHT.
Both the fixed and unfixed combination
reduced the baseline mean untreated 24-h IOP
of 24.6 to 19.2 mmHg [54]. This reduction over
24 h (22%) was less than anticipated or reported
with other fixed combinations.
Combination of an Alpha-2 Agonist
and a Carbonic Anhydrase Inhibitor
Recently, the first fixed combination without a
b-blocker (brinzolamide 1%/brimonidine
tartrate 0.2% ophthalmic suspension,
SimbrinzaTM (Alcon), was approved in the USA
and in several other countries for the treatment
of open-angle glaucoma and OHT. The new
combination is labeled for three-times-daily
administration and its 24-h efficacy remains to
be determined.
Conclusions
Table 1 summarizes the average 24-h efficacy of
commonly used antiglaucoma drug
combinations. Several fixed combinations are
currently available, with a potent IOP-lowering
efficacy, which appears to be fairly uniform
throughout the 24 h. However, few high-quality
trials have assessed the 24-h efficacy of
combined antiglaucoma therapy. These mostly
short-term studies only constitute a small
portion of the literature on the medical
therapy of glaucoma. Given the significant
time-dependent variation of drug efficacy and
the fluctuation of 24-h IOP, and despite the
obvious difficulties in conducting such studies
(higher cost, limited resources, difficulties in
enrolment and logistics, etc.), more effort
should be devoted to adequately document
the circadian efficacy of combined
antiglaucoma therapy.
24-H IOP CONTROL WITH LASER
TRABECULOPLASTY
Since its development, argon laser
trabeculoplasty (ALT) has evolved as a popular
adjunctive or sometimes even initial therapy
option in the management of open-angle
glaucoma [134], either as an intervention
before the instigation of medical therapy
[135], or when greater pressure reduction is
needed to prevent further glaucoma progression
in medically treated patients [136]. In the late
1990s, Latina and coworkers [137] reported
promising results with a new laser technique
called selective laser trabeculoplasty (SLT). Ever
since the initial report, SLT has become a
popular treatment option worldwide and its
use has been advocated as an alternative to ALT.
Although the exact mechanism by which
trabeculoplasty (ALT and SLT) decreases IOP
remains controversial [138], the common view
is that the laser induces structural, biological,
and biochemical changes within the trabecular
meshwork that result in a meaningful
enhancement of outflow facility. Prospective
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and retrospective studies indicate that both ALT
and SLT demonstrate similar efficacy in terms of
IOP control [139–141], but SLT preserves the
trabecular tissue architecture and may be
repeated with greater success than ALT
[142–144].
Although the IOP-lowering efficacy of
trabeculoplasty during office hours [145] and
the effect on long-term variation of IOP has
been well documented previously [146],
information is currently scant on the 24-h
efficacy of laser trabeculoplasty [147]. Agarwal
and coworkers [148] analyzed the long-term
effect of ALT on the circadian IOP
characteristics of Indian patients. The authors
performed 360 ALT in a group of previously
untreated POAG patients (40 eyes of 21
patients) and a group of patients with POAG
who were on medical therapy for more than
1 year (39 eyes of 21 patients). Goldmann
tonometry was performed every 3 h from
4:00 am until 10:00 pm. In the previously
untreated group, mean IOP was reduced from
25.8 ± 3.4 to 18.1 ± 3.2 mmHg (-29.8%) after
5 years of follow-up. In the previously medically
treated group, mean IOP was reduced from
26.1 ± 3.2 to 22.7 ± 3.9 mmHg (-13%) at the
5-year follow-up time-point. The circadian IOP
fluctuation decreased from 7.9 ± 1.4 mmHg at
baseline to 3.6 ± 1.3 mmHg after 5 years of
follow-up in the previously untreated group,
and from 7.7 ± 1.4 mmHg at baseline to
5.8 ± 1.8 mmHg after 5 years in the medically
treated group. The authors concluded that in
this population of patients with POAG with a
heavily pigmented trabecular meshwork, ALT
appears significantly more effective when
employed as primary therapy.
The ability of ALT to improve the circadian
IOP characteristics was first shown by Greenidge
et al. [149] who employed applanation
tonometry to investigate the 24-h IOP
characteristics of 25 patients with glaucoma.
The investigators compared 24-h pre-treatment
IOP data with IOP curves obtained 24 h and
8 weeks after laser therapy. Topical medications
were not modified during the period of this
study. It is worth noting that a pressure
elevation greater than 5 mmHg occurred in
46% of treated patients. In this study, IOP
fluctuation was referred to as ‘IOP irregularity’
(sic) and was defined as the standard deviation
of all measurements in the 24-h cycle.
Following ALT, a significant decrease in mean
(22%), range (30%), fluctuation (25%), and peak
24-h IOP (25%) was found. Interestingly, the
Table 1 Summary of available evidence on the 24-hour efﬁcacy of ﬁxed combination therapies




Latanoprost/timolol 24–34 28–35 16–33 [12, 15, 16, 19, 20, 56, 58, 67, 88, 129]
Travoprost/timolol 33 35 31 [75]
Bimatoprost/timolol 35 38 32 [76, 131]
Dorzolamide/timolol 25–28 30 20–26 [13, 16, 21, 52, 60, 61]
Brimonidine/timolol 22 22 22 [54]
Percentages of IOP reduction from untreated baseline are reported as ranges of means. Figures are derived from the trials
discussed in this review
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authors noted that some patients, despite
having a minimal IOP reduction at a reference
office-hour measurement (1:00 pm),
demonstrated more favorable overall circadian
IOP characteristics following ALT. However,
one of the study limitations was that night
measurements were taken in the sitting
position, after the patient was woken up.
In a 24-h study performed in a sleep
laboratory, Lee and coworkers [150]
investigated the 24-h efficacy of ALT in 28
eyes of 18 patients with open-angle glaucoma
whose target IOP was not reached with topical
medical therapy. Twenty-four-hour pressure
was monitored with a pneumotonometer
every 2 h in the sitting position (at daytime)
and the supine position (during the day and
night) before and approximately 2 months after
laser therapy. Baseline mean daytime sitting
IOP, mean nocturnal supine IOP, and mean
habitual 24-h IOP was 17.3 ± 2.9, 24.7 ± 5.5,
and 19.8 ± 3.4 mmHg, respectively. Following
laser therapy, mean IOP measurements were:
16.6 ± 3.5, 22.8 ± 5.0, and 18.7 ± 3.6 mmHg,
respectively. According to the results of this
study, laser therapy did not meaningfully alter
daytime IOP. In contrast, mean 24-h, peak, and
habitual IOP were all significantly reduced. The
investigators concluded that laser therapy
exhibited minimal daytime, but significant
nocturnal efficacy. Thus, they proposed that
even when patients exhibit a poor response to
laser therapy during office hours there might be
a benefit from laser during the nighttime.
Nonetheless, it remains unclear why this 24-h
study did not detect the daytime efficacy
previously reported by other investigators [1,
148, 149].
Nagar et al. [151] studied the effect of SLT on
diurnal tension curves in patients with OHT
and POAG. Forty patients were included and
randomized to receive 360 SLT treatment or
latanoprost. The authors evaluated the diurnal
pre-treatment IOP as well as post-laser pressures
after 3 days, 1 week, 1 month, and 4 to
6 months. The IOP was measured at 8.00 am,
11.00 am, 2.00 pm, and 6.00 pm (Goldmann
applanation tonometry). The difference
between peak and trough IOP was considered
as the diurnal fluctuation. Success was defined
as a 50% decrease in IOP fluctuation. IOP
decrease was similar in both groups and IOP
reduction at final follow-up visit was
6.2 ± 0.8 mmHg for the SLT group and
7.8 ± 0.8 mmHg for the latanoprost group. The
IOP fluctuation was reduced in both groups;
however, latanoprost was more efficacious (41%
reduction for SLT vs. 64% for latanoprost).
Moreover, latanoprost resulted in higher
success rates compared to 90 and 180 SLT
treatments. The difference in efficacy between
latanoprost and 360 SLT treatment did not
reach statistical significance.
Ko´thy and coworkers [152] were the first to
report the 24-h efficacy of SLT in a group of 26
eyes of 13 patients with POAG who had been
washed out of their topical medical therapy.
The authors reported that no eye showed
evidence of a mean 24-h IOP reduction of 20%
or more. However, the amplitude of 24-h
fluctuation was significantly reduced with SLT.
The investigators concluded that office time
IOP measurements alone might not adequately
portray the overall 24-h efficacy of SLT
treatment.
Recently, Tojo et al. [153] examined the 24-h
effectiveness of SLT in 10 previously treated
Japanese patients with NTG employing the
Sensimed Triggerfish contact lens sensor
(Sensimed AG). This device consists of a
disposable silicone contact lens with a built-in
micro-electromechanical system, which
measures curvature alterations at the
corneoscleral junction induced by IOP
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variations. An antenna mounted around the
patient’s eye receives the data, which are then
transmitted to a recorder. Unfortunately, this
system produces arbitrary units, rather than
actual pressure values. Using this continuous
telemetric platform, the authors established
that in patients with NTG, SLT does not
reduce mean habitual 24-h IOP or mean
diurnal IOP fluctuation, but does reduce
nocturnal IOP fluctuation.
24-H EFFICACY OF SURGERY
IOP reduction remains the mainstay of glaucoma
therapy and the conventional stepwise algorithm
usually involves medical treatment, then laser
trabeculoplasty, and finally surgical techniques.
Surgeryhasbeenshowntoreduce themeanIOPto
acceptable safe levels, providing long-term
daytime IOP control and optic disc and visual
field stability [29, 125, 154–163]. IOP isnot a static
parameter but instead undergoes dynamic
changes. Therefore, implied in the definition of
target IOP is a dampening of its cyclic fluctuations
throughout the day, as these diurnal variations
have been identified as a significant and
independent risk factor in glaucomatous
progression [5, 8, 9, 34, 84, 155, 156].
Evaluating the 5-year efficacy of
trabeculectomy in controlling IOP, Saiz et al.
[157] reported a diurnal range of
4.8 ± 2.5 mmHg for the period between
8:00 am and 6:00 pm, in 14 patients with
open-angle glaucoma. Gandolfi et al. [158]
documented the diurnal range (8:00 am to
6:00 pm with measurements every 2 h) to be
10–17 mmHg in patients who underwent a
trabeculectomy with adjunctive 5-fluorouracil
versus 14–22 mmHg in those patients who had
a trabeculectomy without the antimetabolite.
Medeiros et al. [159] compared the mean,
peak IOP and daytime diurnal pressure (8:30 am
to 5:00 pm with measurements every 3 h) in a
group of well controlled with medical therapy
patients with glaucoma (n = 30) versus a group
which underwent trabeculectomy (n = 30). The
authors did not detect a statistically significant
difference in mean IOP between the two groups.
In contrast, diurnal fluctuation of IOP was
significantly greater in the medically treated
group compared to the surgical group (3.2 ± 1.5
vs. 2.2 ± 1.7 mmHg). In addition, medically
controlled patients had higher peak IOP and
demonstrated greater fluctuation after a
water-drinking test [159]. In another
prospective study, Konstas and coworkers [29]
investigated the 24-h pressure characteristics in
patients with advanced open-angle glaucoma
who had either undergone successful
trabeculectomy or were considered well
controlled under maximal medical treatment.
Each group consisted of 30 patients matched for
daytime IOP (10:00 am). The authors
established that successful trabeculectomy
provides a statistically lower mean, peak, and
fluctuation of 24-h IOP [29]. Specifically, they
reported the 24-h fluctuation of IOP to be
2.3 ± 0.8 mmHg in the surgical group and
4.8 ± 2.3 mmHg in the medically treated
group. A more recent study by Mansouri et al.
[160] compared the quality of diurnal IOP
control during a water-drinking test in
patients with POAG who were either well
controlled with latanoprost monotherapy
(n = 20), or had had successful trabeculectomy
(n = 20) or deep sclerectomy with collagen
implant (DSCI; n = 20). These authors
observed that mean IOP during the diurnal
period (8:00 am to 5:00 pm) was significantly
lower with trabeculectomy (10.1 mmHg) or
DSCI (13.7 mmHg) compared with latanoprost
monotherapy (15.7 mmHg). Nevertheless, the
IOP fluctuation was similar between the surgical
and the medical groups. Additionally, during
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the water-drinking test the IOP elevation was
significantly greater for the latanoprost-treated
group (5.2 mmHg) than the trabeculectomy
(2.4 mmHg) and DSCI groups (3.8 mmHg)
[160].
Matsuoka et al. [161] investigated the effect
of combined trabeculotomy and sinusotomy on
the 24-h IOP characteristics in treated patients
with open-angle glaucoma [161]. The authors
analyzed 14 eyes of 8 patients with office-hour
IOP \17 mmHg who exhibited IOP peaks
[20 mmHg outside office hours. The mean
24-h and peak IOP values were reduced by
15.1% and 26.3%, respectively, while the
24-h fluctuation was reduced by 41.3% after
a minimum follow-up period of 3 months
following surgery.
Klink et al. [162] investigated the effect of
trabeculectomy on the habitual diurnal and
nocturnal IOP fluctuations in 35 eyes with
open-angle or chronic angle-closure glaucoma.
Study patients were treated with 2.0 ± 1.2
antiglaucoma medications preoperatively and
0.14 ± 0.4 medications postoperatively. The
mean follow-up time was 2.1 ± 1.7 years.
Although the authors do not present mean
24-h pressures, they report that the diurnal
fluctuation was significantly reduced from
12.1 ± 4.2 mmHg preoperatively to
5.6 ± 2.2 mmHg postoperatively (54%
reduction) and the nocturnal fluctuation was
reduced from 7.1 ± 4.5 mmHg to 3.9 ± 4.1
(46% reduction). The peak diurnal and
nocturnal preoperative IOP values (26.5 ± 5.9
and 23.4 ± 5.2 mmHg, respectively) were also
significantly reduced (16.0 ± 4.4 and
16.0 ± 5.4 mmHg, respectively).
Recently, Liang et al. [163] described the IOP
characteristics of 176 patients with primary
angle-closure glaucoma (PACG) who had had
trabeculectomy with mitomycin C. Goldmann
tonometry measurements were performed from
5:00 am till 10:00 pm in the third postoperative
month. The mean IOP was 13.2 ± 3.7 mmHg
and the mean fluctuation was 3.8 ± 2.1 mmHg.
It is worth noting that in this surgical cohort, 34
of 176 patients (19%) exhibited peak IOP
readings [18 mmHg. The authors established
that IOP fluctuation was positively associated
with higher mean and peak IOP and negatively
associated with the extent of the bleb area and
the presence of microcysts within the bleb.
In another investigation Sihota et al. [43]
compared the IOP characteristics of healthy
controls (n = 75) and patients with newly
diagnosed POAG (n = 60) or PACG following
laser iridotomy (n = 75) by performing IOP
measurements between 7:00 am and 10:00 pm.
The authors documented that IOP fluctuation
was significantly greater in the PACG group
(7.7 ± 3.0 mmHg) and in the POAG group
(8.3 ± 2.6 mmHg) compared to normal
controls (4.8 ± 2.5 mmHg). Importantly, in
this study morning peaks were more frequent
in POAG eyes, whereas afternoon peaks were
more common in controls and in the PACG
eyes.
THE FUTURE OF 24-H IOP
MONITORING IN GLAUCOMA
It is possible to envisage a day in the future
when a resident will ask us: ‘‘is it really true that
there was a time when glaucoma diagnosis and
treatment relied exclusively on IOP
measurements once every three months?’’ The
answer will, of course, be: ‘‘Yes’’, because this is
what usually happens today. As a matter of fact,
we measure IOP infrequently, usually once
every time a patient with glaucoma visits the
ophthalmologist. If the IOP measurement does
not give rise to suspicion, it will be evaluated
once again after several months or, in many
cases, only after years, at any time during the
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day, according to the patients’ convenience and
the time of follow-up visit. This reflects what is
presently done and that is how it is reimbursed
by most healthcare systems and the various
insurance companies. Undoubtedly, this cannot
be sufficient. There is now comprehensive
evidence that IOP fluctuates considerably
during the 24-h period and may be quite
different in the prone and supine position and
relatively high in the early morning hours. This
is what we know from evidence emerging from
studies of small patient cohorts. But in most
cases we can only guess what the real 24-h IOP
of the individual patient may be.
Surely, we must strive to acquire a more
comprehensive understanding of what is going
on with the pressure of the individual patient
with glaucoma. We need to check pressures
more often than once, ideally outside the ‘office
hours’ and if possible at night when patients are
asleep. Few academic centers have the ability
and expertise to do this routinely right now. In
Germany in-patient diurnal IOP monitoring is
being reimbursed and may encompass
nighttime IOP measurements if equipment,
expertise and logistics allow. This may be one
of the reasons why in Germany we tend to see
significantly fewer NTG cases than is reported in
other parts of the world. Many of those patients
diagnosed with NTG demonstrate elevated IOPs
outside office hours and, hence, are
subsequently classified as POAG cases. This
phenomenon has been already highlighted by
Gloor and Meier-Gibbons in 1996 [164].
Unfortunately, it should not be assumed that
in the future IOP monitoring at the hospital
setting is going to be introduced in many
countries owing to cost considerations. Even in
centers where 24-h monitoring is routinely
performed, we measure the IOP only 5 or 6 times
and rarely more often. This approach does not
resemble systemic blood pressure monitoring.
Indeed, all the IOP measurements obtained
within a 24-h curve may only reveal a few
minute glimpse of the pressure pathology in a
given glaucoma patient. Consequently, for the
rest of the 24-h period the true IOP values remain
largely unknown. The same holds true during
sports, when blowing a musical instrument or
indeedwithanyother activity that influences IOP.
Thus, new reliable IOP measurement
technologies are needed in the future. An
IOP-sensitive contact lens or an intraocular
implant may soon be clinically widely
available. Significant issues remain to be
addressed with regard to reliability, cost, and
practicality of all new technologies bearing in
mind that virtually all IOP evidence currently
available from controlled trials and obtained in
clinical practice rely on Goldmann technology.
Furthermore, even if successful new
technologies will not solve all the problems we
face, quite the opposite: they will offer new
insight into true IOP physiology so that
subsequently we may have to change the
definition and management of POAG, OHT,
and NTG. In fact, Mansouri and Shaarawy [165]
have published initial clinical results with a
novel wireless ocular telemetry sensor
(Sensimed AG) for IOP monitoring in patients
with open-angle glaucoma. The device consists
of a disposable silicone contact lens with a
built-in micro-electromechanical system, which
measures alterations in corneal curvature
presumably induced by IOP variations. An
antenna mounted around the patient’s eye
receives the data, which are then transmitted
to a recorder. Although the authors reported
encouraging first results with 24-h ambulatory
signal measurements in 15 patients with
open-angle glaucoma, a recent study by Hollo´
et al. [166] found that the arbitrary units
produced during a 24-h curve with Sensimed
measurements had no apparent correlation
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with Goldmann IOP readings in a cohort of
patients with open-angle glaucoma who were
assessed at baseline and after 3 months of
prostaglandin treatment. In addition, the
device did not detect any IOP changes induced
by the patients’ transition from the sitting
(wake period) to the supine (sleeping period)
position. These authors concluded that the
currently available commercial version of the
device cannot be used in a clinical setting to
monitor the IOP reduction induced by therapy,
and has limited value in identifying transient
IOP changes. Hopefully in the future there will
be more reliable technologies continuously
monitoring IOP in millimeters of mercury
with Goldmann or equivalent technologies.
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